Cipher Pharmaceuticals Inc.

Latest

Jul 02, 2020, 18:00 ET Cipher Pharmaceuticals Appoints New Chief Financial Officer

OAKVILLE, ON, July 2, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its...


May 07, 2020, 20:00 ET Cipher Pharmaceuticals Reports First Quarter 2020 Financial Results

Earnings per common share increases to $0.10 ($0.13 in Canadian Dollars1) OAKVILLE, ON, May 7, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its...


Apr 27, 2020, 21:56 ET Cipher Pharmaceuticals Schedules Q1 2020 Earnings Release and Conference Call

OAKVILLE, ON, April 27, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The...


Mar 25, 2020, 18:00 ET Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter OAKVILLE, ON, March 25, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the...


Feb 20, 2020, 17:00 ET Notice of Cipher Pharmaceuticals Q4 2019 Conference Call

OAKVILLE, ON, Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March...


Feb 06, 2020, 17:30 ET Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical

OAKVILLE, ON, Feb. 6, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") is pleased to announce that Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), the Company's U.S....


Jan 20, 2020, 18:00 ET Cipher Pharmaceuticals Receives Notice of Termination from Bausch

OAKVILLE, ON, Jan. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Termination (the "Notice") from Bausch Health...


Nov 07, 2019, 07:00 ET Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

Revenue increased 20% to $5.8 million OAKVILLE, ON, Nov. 7, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the...


Oct 24, 2019, 17:00 ET Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

OAKVILLE, ON, Oct. 24, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results conference call on Thursday,...


Oct 18, 2019, 07:00 ET Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)

OAKVILLE, ON, Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®...


Aug 09, 2019, 07:00 ET Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

Company also provides update on strategic priorities MISSISSAUGA, ON, Aug. 9, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and...


Jul 30, 2019, 07:30 ET Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

OAKVILLE, ON, July 30, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2019 financial results conference call on Friday, August 9, ...


Jul 29, 2019, 09:00 ET Cipher Pharmaceuticals Announces Management Change & Preliminary Q2 Financial Highlights

Company also forms Special Committee MISSISSAUGA, ON, July 29, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named...


May 10, 2019, 07:00 ET Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

Revenue increased by 12% to $5.1 million OAKVILLE, ON, May 10, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for...


May 01, 2019, 07:30 ET Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

OAKVILLE, ON, May 1, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10,...


Mar 26, 2019, 07:00 ET Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

OAKVILLE, ON, March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of...


Mar 20, 2019, 07:00 ET Cipher Pharmaceuticals Announces Change to Management Team

OAKVILLE, ON, March 20, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has...


Mar 19, 2019, 07:00 ET Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Canadian product revenue increased 30% to $6.9 million for the year Completed six (6) strategic business transactions enhancing long-term value OAKVILLE, ON, March 19, 2019 /CNW/ - Cipher...


Mar 15, 2019, 17:05 ET Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

OAKVILLE, ON, March 15, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2018 financial results conference call on Tuesday, March...


Dec 18, 2018, 07:00 ET Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of...


Dec 17, 2018, 07:00 ET Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation...


Dec 05, 2018, 11:00 ET Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

MISSISSAUGA, ON, Dec. 5, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at...


Dec 04, 2018, 07:00 ET Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

MISSISSAUGA, ON, Dec. 4, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined...


Nov 07, 2018, 07:00 ET Cipher Pharmaceuticals Reports Q3 2018 Results

Canadian product revenue increased 27% MISSISSAUGA, ON, Nov. 7, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for...


Oct 24, 2018, 17:05 ET Notice of Cipher Pharmaceuticals Q3 2018 Conference Call

MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday,...